DORTMUND, Germany—InterMed Discovery (IMD) acquired unique microbial omega-3 fatty acid production strains and related technology from the University of Saarland, Saarbrucken, Germany; financial terms were not disclosed. According to the company, the microbial source has the potential to sustainably and reliably produce significantly yields of omega-3 fatty acids, with favorable levels of the long-chain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
“These microbial strains offer not only a new sustainable and reliable source of omega-3, but also give us the capability to develop products with outstanding quality at competitive pricing,” said Bernard Becker, managing director of InterMed Discovery. “This new microbial source, in conjunction with our world-class technology platform, gives us the leading edge in this competitive market and further enhances the reputation of our functional ingredients business.”
